Clinical Trials Logo

Pancreatic Neuroendocrine Tumor clinical trials

View clinical trials related to Pancreatic Neuroendocrine Tumor.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05800106 Completed - Clinical trials for Renal Cell Carcinoma

A Bioequivalence Study of Sunitinib Malate Capsules.

Start date: December 4, 2018
Phase: Phase 1
Study type: Interventional

A randomized, open, two-period, two-sequence crossover trial design used to assess the pharmacokinetics and safety of Sunitinib Malate Capsules in healthy volunteers under fed condition, and compare the bioequivalence of Sunitinib Malate Capsules produced by Pfizer and Chia Tai Tianqing Pharmaceutical Group Co., Ltd, respectively.

NCT ID: NCT05476978 Completed - Clinical trials for Pancreatic Ductal Adenocarcinoma

Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions

Start date: July 1, 2022
Phase:
Study type: Observational

We aim to develop an EUS-AI model which can facilitate clinical diagnosis by analyzing EUS pictures and clinical parameters of patients.

NCT ID: NCT05171517 Completed - Clinical trials for Pancreatic Carcinoma

Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy

Start date: January 1, 2022
Phase:
Study type: Observational

Study objective: To describe the microflora characteristics of the pancreatic solid lesions via the tissue acquired via the endoscopic ultrasound-guided fine needle aspiration/biopsy (EUS-FNA/B). Study design: This is a prospective observational study.

NCT ID: NCT03967951 Completed - Clinical trials for Pancreatic Neuroendocrine Tumor

CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms

Start date: March 23, 2019
Phase:
Study type: Observational

The aim of this study is to quantify inter-observer variability in delineating pancreatic neuroendocrine neoplasm (PanNEN) on Computerized Tomography (CT) images and its impact on radiomic features (RF), subsequently to this determination, to use CT texture analysis to predict, histological characteristics of PanNEN on CT scans.

NCT ID: NCT03147768 Completed - Clinical trials for Pancreatic Neoplasms

Laser Tissue Welding - Distal Pancreatectomy Sealing Study

LTW
Start date: January 1, 2018
Phase: Phase 1
Study type: Interventional

The laser tissue welding device is intended for use in patients requiring sealing of the pancreas after partial pancreatectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure. The hypothesis is that the laser tissue welding device is safe and effective in sealing the pancreas, thereby decreasing the blood loss (operative and post-operative), and pancreatic juice leakage for patients when the Laser Tissue Welding device is used after pancreatic resection.

NCT ID: NCT02355535 Completed - Solid Tumor Clinical Trials

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

Start date: February 2015
Phase: Phase 1
Study type: Interventional

This Phase I dose escalation study will evaluate Procaspase Activating Compound-1 (PAC-1), a small molecule that activates procaspase -3 to caspase-3, resulting in apoptosis of cancer cells, in patients with advanced malignancies. As of March 1, 2019, only patients with neuroendocrine tumors will be enrolled in Component 1 of this study. PAC-1 is taken orally on days 1-21 of a 28-day cycle. The maximum tolerated dose (MTD) of PAC-1 (5 dose levels) will be determined using a modified-Fibonacci dose-escalation 3+3 design. Treatment continues until disease progression, unacceptable toxicity, physician discretion, or patient refusal.

NCT ID: NCT02159989 Completed - Clinical trials for Advanced Malignant Solid Neoplasm

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Start date: June 18, 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of sapanisertib and ziv-aflibercept in treating patients with solid tumors that have come back (recurrent) and have spread to another place in the body (metastatic) or cannot be removed by surgery (unresectable). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ziv-aflibercept may stop the growth of solid tumors by blocking the growth of new blood vessels necessary for tumor growth. Giving sapanisertib with ziv-aflibercept may kill more tumor cells.

NCT ID: NCT01466036 Completed - Clinical trials for Pancreatic Neuroendocrine Tumor

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Start date: July 2012
Phase: Phase 2
Study type: Interventional

Cabozantinib works by blocking the growth of new blood vessels that feed a tumor. In addition to blocking the formation of new blood cells in tumors, cabozantinib also blocks pathways that may be responsible for allowing cancers cells to become resistant to other "anti-angiogenic" drugs. Cabozantinib has been studied or is being study in research studies as a possible treatment for various types of cancer, including prostate cancer, brain cancer, thyroid cancer, lung cancer, and kidney cancer. In this research study, the investigators wish to learn if cabozantinib is effective in treating patients with pancreatic neuroendocrine and carcinoid tumors.

NCT ID: NCT01024387 Completed - Clinical trials for Pancreatic Neuroendocrine Tumor

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Start date: March 2010
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine the effectiveness of AMG 479 against carcinoid and pancreatic neuroendocrine tumors. AMG 479 is an antibody that is made in the laboratory. Antibodies are highly specific proteins produced by the body's immune system that recognize foreign substances in the body. AMG 479 has been used in other research studies and information from those other research studies suggests that AMG 479 may help to prevent the growth of some neuroendocrine tumors. The observed antitumor activity of AMG 479, together with the current limited treatment options available for patients with neuroendocrine tumors, warrant further investigation of AMG 479 in this patient population.

NCT ID: NCT00970970 Completed - Clinical trials for Renal Cell Carcinoma

Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease

VHLimage
Start date: September 2009
Phase:
Study type: Observational

Von Hippel Lindau disease (VHLD) is an inherited syndrome characterized by vascular malformations, kidney cancer, adrenal gland and pancreas tumors. The VHL protein is not functional in the different disease associated lesions which results in production of high amounts of vascular endothelial growth factor (VEGF). Currently there are no clinical, radiographic or molecular markers that can predict the natural history of a given lesion. With 89Zr-bevacizumab positron emission tomography (PET) scanning, VEGF can be visualized and quantified. The investigators hypothesize that 89Zr-bevacizumab PET imaging is a useful tool to predict the behaviour of disease associated lesions in patients with VHLD. Adult patients with VHLD who have had routine magnetic resonance imaging (MRI) scans of central nervous system (CNS) and abdomen will undergo a 89Zr-bevacizumab PET scan. MRI will be repeated within 12 months.